AUG 1 9 2004

FAX



То	Attn: Examiner Jeffrey S. Parkin, Group 1648				
Company	USPTO				
Fax	703-872-9306				
From	Marjorie J. Pfeiffer				
Tel	1-919-483-9038; Facsimile: 1-919-483-7988				
E-mail	marjorie.j.pfeiffer@qsk.com				
Date	August 19, 2004 Pages including cover 39				
Subject	Response to Office Action				

GlaxoSmithKline PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27708

Tel: 919 483 2100 www.gsk.com

Re:

Application of James Martin LENHARD et al.

U.S. Serial No.: 09/889,471; Filed: July 17, 2001

Title: Methods of Screening Protease Inhibitors, of Inducing Mice Susceptible to HIV Protease Inhibitor-induced Dyslipidemia,

and Genes Associated Therewith Attorney Docket No. PU3610USw

Attached:

- 1. Transmittal Form with a Certificate of Transmission (37 CFR 1.8(a))
- 2. Petition and Fee for Extension of Time (in duplicate)
- 3. Response and Amendment (6 pages)
- Copies of International Search Report references for PCT/US00/01205 as follows:
 Carr et al. (8 pages); Shaw et al. (5 pages); Carr et al. (3 pages)Shimomura et al. (13 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient of the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

			Palent and Trade	PTC/SB/21 (08-03) proved for use through 07/31/2008, OMB 0851-0031 smark Office: U.S. DEPARTMENT OF COMMERCE		
Under the Paperwe	ork Reduction Act of 1995, n	o persons are required	to respond to a collection of micros	ation unless it displays a valid OMB control number.		
TRANSMITTAL			Application Number	09/889,471		
			Filing Date	July 17, 2001		
FORM		; First Named Inventor	Jemes Martin LENHARD			
(to be used for all correspondence after initial filing)		r inilial filing)	Art Unit	1648		
			Examiner Name	Parkin, Jeffrey S.		
Total Number of Pages in This Submission			Altomey Docket Number	PU3610USw		
ENCLOSURES (check all that apply)						
Fee Transmitte	al Form	Drawing(s) '	After Allowance communication , to Group		
F66 Al	tached	Licensing	-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment / Reply		Petition		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After Final			: o Convert a al Application	Proprietary Information		
Affidavits/declaration(s)		Power of Change of	Attorney. Revocation f Correspondence	Status Letter		
Extension of Time Request		Terminal	Disclaimer Disclaimer	Other Enclosure(s) (please identify below):		
Express Abandonment Request		Request	or Refund	Copies of references (4) cited in the International Scarch Report for PCT/US00/01205 from which		
Information Disclosure Statement		CD, Num	ber of CD(s)	this application claims priority		
Certified Copy of Priority Document(s)		Remarks	· ///	<u> </u>		
Response to Missing Parts/ Incomplete Application						
Response to Missing Parts						
under 37 CFR 1.52 or 1.53			!	•		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
or	Michael M. Conger Registration No. 43,56 Telephone: (919)483-2	52 2474				
Signature	7) (<u> </u>			
Data August / 8 2004				•		
Date August / 8 , 2004						
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby confly that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the						
Typed or printed name Marjoric J. Ptelffer		ſſer				
Signature Mayarie & Kley			liffer Date	August /9 , 2004		
This collection of Information is required by 37 CFR/15. The formation is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality 15 governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.						

If you need essistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

Attorney Dkt. No. PU3610USw

AUG 1 9 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James Martin LENHARD

Serial No.: 09/889,471

Unit: 1648

Filed: July 17, 2001

Examiner: Parkin, Jeffrey S

For:

Methods Of Screening Protease Inhibitors, Of Inducing Mice Susceptible To HIV Protease Inhibitor-Induced Dyslipidemia, and Genes Associated Therewith

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE AND AMENDMENT

Sir:

This paper is submitted in response to the Office Action mailed February 23, 2004 (Paper No. 02212004) for which a three month shortened statutory period to respond was set. A petition for a three-month extension of time is included herewith.